Physician profile
Brad J Reedy
NPI 1164519443
$896.27
in general payments reported to CMS, 2019-2025
20 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.91 · 2021: $48.86 · 2022: $51.51 · 2023: $149 · 2024: $308 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.99 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $187.64 | 2024-2025 | Veozah |
| Novo Nordisk INC | $97.00 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $84.56 | 2024-2025 | Airsupra, Farxiga |
| Inspire Medical Systems, INC. | $74.38 | 2023 | Inspire |
| Abbvie INC. | $73.34 | 2021-2024 | |
| Lilly USA, LLC | $60.44 | 2021-2025 | Kisunla, Amyvid |
| Hologic Sales and Service, LLC | $44.10 | 2025 | Thinprep 2000 Processor, Aptima |
| Eisai INC. | $30.01 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $26.75 | 2023 | Nuedexta |
| Aimmune Therapeutics, INC. | $24.88 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2020 | |
| Seqirus USA INC | $24.17 | 2025 | Flucelvax, Fluad |
| Amgen INC. | $22.27 | 2021 | |
| Sumitomo Pharma America, INC. | $21.40 | 2024 | Gemtesa |
| Dexcom, INC. | $20.15 | 2023 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18.74 | 2020 | |
| Gilead Sciences, INC. | $18.24 | 2022 | |
| Pfizer INC. | $16.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.73 | 2023 | Xifaxan |
| Merz North America, INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Reedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.